Patient-reported outcome measures in a pharmacokinetic study with sunitinib, a prospective cohort study

PURPOSE: During treatment with tyrosine kinase inhibitors, such as sunitinib, patients experience treatment and/or disease-related symptoms. Although application of patient-reported outcome measures (PROMs) enhances early recognition of symptoms, early clinical trials are focused on symptom severity...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Support Care Cancer
Auteurs principaux: Koldenhof, J. J., Lankheet, N. A. G., Steeghs, N., Teunissen, S. C. C. M., Witteveen, P. O.
Format: Artigo
Langue:Inglês
Publié: Springer Berlin Heidelberg 2018
Sujets:
Original Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6018583/
https://ncbi.nlm.nih.gov/pubmed/29464389
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00520-018-4075-7
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires